CADL Stock Overview A clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. More details
Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Candel Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Candel Therapeutics Historical stock prices Current Share Price US$8.55 52 Week High US$14.60 52 Week Low US$1.34 Beta -1.24 1 Month Change 10.04% 3 Month Change 98.84% 1 Year Change 405.92% 3 Year Change 90.85% 5 Year Change n/a Change since IPO 22.14%
Recent News & Updates See more updates Candel Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.966671 million. Candel Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.966671 million.
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight Dec 11
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway Jul 01
Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024 May 31
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting May 25
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer Apr 15
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors Apr 12
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Apr 05
New major risk - Share price stability Apr 05
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma Mar 29
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate Mar 06
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma Feb 15 Candel Therapeutics, Inc. Announces Chief Financial Officer Changes
Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer Dec 13
Candel Therapeutics Receives Non-Compliance Notice from Nasdaq Nov 24
Candel Therapeutics Receives Non-Compliance Notice from Nasdaq Nov 22
Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022) Nov 10
New major risk - Share price stability Nov 07
Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Nov 04
Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 Oct 20
Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 Oct 19
Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer Sep 27
Price target increased by 8.6% to US$9.50 Sep 19
First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022) Aug 14
New major risk - Financial position Jul 01
New major risk - Share price stability Jun 25
Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors Jun 09
Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023 May 25
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting May 20
Price target decreased by 17% to US$7.25 May 16
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021) Mar 31
Independent Director recently bought US$73k worth of stock Dec 13
Consensus forecasts updated Dec 10
Price target decreased to US$11.60 Dec 09
Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer Dec 09
Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting Nov 19
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11
Candel gets European orphan drug designation for brain, spinal cord tumor treatment Sep 15 Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022
Candel Therapeutics appoints CFO, chief medical officer Sep 07
Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022 Sep 03
Consensus forecasts updated Aug 31
Consensus forecasts updated Aug 17
Less than half of directors are independent Aug 10
First half 2022 earnings released Aug 05
Candel Therapeutics, Inc. Announces Executive Changes Aug 02
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index Jun 26
Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer May 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 13
Consensus forecasts updated Apr 05
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 30
Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409 Mar 30
Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer Mar 04
Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer Mar 03
Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer Feb 04
Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board Feb 01
Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409 Dec 11
Third quarter 2021 earnings released: US$0.69 loss per share Nov 15
Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies Oct 21
Chairman recently bought US$411k worth of stock Jul 31 Shareholder Returns CADL US Biotechs US Market 7D 6.5% -4.8% -0.5% 1Y 405.9% -3.2% 21.1%
See full shareholder returns
Return vs Market: CADL exceeded the US Market which returned 23.1% over the past year.
Price Volatility Is CADL's price volatile compared to industry and market? CADL volatility CADL Average Weekly Movement 30.4% Biotechs Industry Average Movement 11.3% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.2% 10% least volatile stocks in US Market 3.0%
Stable Share Price: CADL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CADL's weekly volatility has decreased from 44% to 30% over the past year, but is still higher than 75% of US stocks.
About the Company Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
Show more Candel Therapeutics, Inc. Fundamentals Summary How do Candel Therapeutics's earnings and revenue compare to its market cap? CADL fundamental statistics Market cap US$352.12m Earnings (TTM ) -US$52.20m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CADL income statement (TTM ) Revenue US$0 Cost of Revenue US$25.57m Gross Profit -US$25.56m Other Expenses US$26.63m Earnings -US$52.20m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.23 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -97.8%
How did CADL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 00:24 End of Day Share Price 2025/02/12 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Candel Therapeutics, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Evan Seigerman BMO Capital Markets Equity Research Alec Stranahan BofA Global Research Judah Frommer Credit Suisse
Show 2 more analysts 
